Planet Briefing

First published · Last updated

Chemotherapy plus camrelizumab for fertility preservation (NACI-F) in FIGO stage IB1 cervical cancer: a multicenter, single-arm, phase 2 trial

A multicenter, single-arm phase 2 trial testing chemotherapy plus camrelizumab for fertility preservation in FIGO stage IB1 cervical cancer is reported as a journal article. The supplied source fields include no trial results, sample sizes, locations, or outcomes.

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence
6/10
Geographic reach
3/10
Global importance
2/10
Impact magnitude
2/10
Positivity
5/10
Urgency
1/10

Why it matters

This trial pertains to fertility-preserving treatment research for early-stage cervical cancer.

Sources

Report an issue